Advanced Recomp Stack (peptidedosingprotocols.com)

How it works

The Advanced Recomp Stack combines retatrutide with CJC-1295 (No DAC) and ipamorelin to achieve a synergistic effect on body recomposition. Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors. This activation leads to appetite suppression, improved fat handling, and increased fat burning, making it the strongest weight-loss peptide currently in clinical development. Specifically, GLP-1 reduces appetite and slows digestion, GIP enhances fat and insulin management, and glucagon signals the liver to burn stored fat. This triple action is why retatrutide is more effective than single-receptor drugs like semaglutide.

CJC-1295 (No DAC) is a short-acting GHRH analog that stimulates the pituitary gland to release growth hormone (GH) in a natural pulse pattern. The No DAC version is preferred as it mimics the body's natural GH release, unlike the with-DAC version, which maintains elevated GH levels for extended periods. Ipamorelin, on the other hand, is a selective GH secretagogue that activates the ghrelin receptor to promote GH release. When combined, CJC-1295 and ipamorelin amplify the GH pulse beyond what either peptide can achieve alone.

The rationale for stacking these compounds lies in the fact that rapid weight loss often results in muscle loss alongside fat loss. The combination of CJC-1295 and ipamorelin is intended to elevate GH and IGF-1 levels, which are crucial for preserving lean muscle mass, enhancing recovery, improving sleep quality, and facilitating connective tissue repair during a caloric deficit. Importantly, retatrutide and the CJC-1295/ipamorelin combination operate through different biological systems, targeting metabolic receptors and growth hormone receptors, respectively. This lack of overlap ensures that they do not compete with each other, making the combination pharmacologically rational.

While there is no clinical trial that has tested the combination of retatrutide, CJC-1295, and ipamorelin together, the individual compounds have been studied extensively. The strongest evidence for efficacy comes from retatrutide, which has shown significant weight loss in Phase 2 and Phase 3 trials. The dosing protocols for CJC-1295 and ipamorelin are based on published pharmacokinetic and pharmacodynamic data, as well as community practices, rather than direct clinical trials for the stack itself. [Source: Peptide Dosing Protocols]

Plain language: The Advanced Recomp Stack helps with weight loss and muscle retention by combining retatrutide, which suppresses appetite and burns fat, with CJC-1295 and ipamorelin, which boost growth hormone levels to preserve muscle.

Who should avoid it

Individuals with a history of pancreatitis should avoid this stack due to the potential risk associated with GLP-1 receptor agonists. Those with a known hypersensitivity to any of the components should also refrain from using this stack. Additionally, individuals with a history of cardiovascular issues should exercise caution, particularly due to retatrutide's effect on heart rate. Pregnant or breastfeeding women should avoid this stack as safety has not been established in these populations. Lastly, individuals with pre-diabetes or insulin resistance should monitor their blood glucose levels closely, as the stack can influence blood sugar control in both directions. [Source: Peptide Dosing Protocols]

Plain language: People with pancreatitis, cardiovascular issues, or those who are pregnant should avoid this stack.